Morgan Lewis

Related Publications

06/28/12 Healthcare Reform Law Stands—With Modifications to State Medicaid Expansion
The U.S. Supreme Court held that the Patient Protection and Affordable Care Act of 2010 (P.L. 111-148 or ACA) is constitutional with modifications to the Medicaid expansion provisions.
06/16/09 BioBucks Meets PharmacoEconomics: Who's Got the Negotiating Leverage Now? presented at Allicense Conference, San Francisco
03/11/09 Tales from the Front: Lessons Learned, Best Practices, and What to Avoid, presented at ACI's Life Sciences M&A Conference, New York
View all publications

Related News

06/26/14 New Jersey Powerhouse: Morgan Lewis & Bockius, Law360
Law360 highlights Morgan Lewis's Princeton office as a New Jersy Powerhouse, and interviews partners Steve Cohen and Randy Sunberg.
01/27/14 Licensing Deals Still Backloaded In 2013, But Biotechs Could Gain Leverage, The Pink Sheet
Business and Finance partner Randy Sunberg is quoted.
10/03/13 Morgan Lewis Receives 2013 LMG Life Sciences Awards
Morgan Lewis was named Healthcare Pricing and Reimbursement Firm of the Year at the inaugural LMG Life Sciences awards ceremony.
View all news

Emerging Business Tools

visit the Entrepreneur Resource Headquarters
Photo of  Randall B. Sunberg

honors + affiliations

Member, American Bar Association, Business Law Section

Listed as Recommended in Life Sciences Commercial and Partnering by PLC Cross-border Life Sciences Handbook (2007/2008)

Listed, Chambers USA: America's Leading Lawyers for Business (2006, 2008–2014)

Listed, Elite Leading Lawyers List for Healthcare: Life Sciences, Legal 500 United States (2013–2014)

Listed as Recommended in Life Sciences Commercial and Partnering, PLC Which Lawyer? Yearbook 2008

Listed, New Jersey Super Lawyers (2005–2009)

Recipient, Philadelphia Business Journal Inaugural Life Sciences Award for Best Consultant (Later Stage) (2010)

Listed, Legal Media Group's Life Sciences "Life Sciences Star" – Transactional (2012–2013)

Listed, Law360 Healthcare MVP (2012)

bar admissions

  • New Jersey
  • Pennsylvania
  • New York
  • Missouri
print profile

Randall B. Sunberg
Partner


Email: rsunberg@morganlewis.com
Princeton
502 Carnegie Center
Princeton, NJ 08540-6289
United States of America
Phone: +1.609.919.6606
Fax: +1.609.919.6701

Randall B. Sunberg is a partner in Morgan Lewis's Business and Finance Practice, vice chair of the firm's Life Sciences Interdisciplinary Group, co-chair of the firm's Life Sciences Transactions Practice, and Managing Partner of the Princeton office.

Mr. Sunberg's clients range from early-stage biotechnology start-ups to global pharmaceutical companies, as well as specialty pharma, medical device, diagnostics, and other technology companies. He also advises private equity, venture capital, and investment banking firms focused on the life sciences industry. Mr. Sunberg's background includes a variety of transactions, including negotiating and structuring complex collaborations, mergers and acquisitions, divestitures, joint ventures, corporate partnering and licensing, and the equity investments that often accompany such transactions. Related matters include: alternative financing arrangements such as royalty monetizations; technical contractual arrangements for drug discovery, development, manufacturing and supply; marketing and co-promotion transactions; and outsourcing in the life sciences industry. He also advises boards of directors and significant shareholders on disclosure issues, corporate communications policies, and fiduciary duty matters.

Mr. Sunberg has spoken on the subjects of mergers and acquisitions, strategic alliances, and licensing and collaboration transactions in the United States at Allicense, BIO Annual Meetings and LES Annual Meetings, in Canada at BIOMedex, and in China at BIOForum, as well as at other life-sciences-related conferences and as guest lecturer at the Rutgers Business School MBA Biotechnology Commercialization Concentration.

Mr. Sunberg is admitted to practice in New Jersey, Pennsylvania, New York, and Missouri.

Selected Representations

  • Brickell Biotech in a license agreement with Merz Pharmaceuticals to develop and commercialize a novel retinoid compound for the treatment of skin conditions
  • Shire in its expanded R&D collaboration with arGEN-X for antibody discovery against targets focused on rare diseases
  • Merck in its $14.2 billion agreement to sell its consumer care business to Bayer
  • Eli Lilly in its license agreement with Sanofi for the potential Rx-to-OTC switch of Cialis®
  • Amarin in its co-promotion agreement with Kowa Pharmaceuticals for Amarin’s flagship product, Vascepa®, in the United States
  • CoLucid Pharmaceuticals in its collaboration with IlDong Pharmaceutical relating to the development and commercialization of Lasmiditan in South Korea and southeast Asia
  • Lundbeck in its up to €100 million collaboration (plus royalties) with Otsuka Pharmaceutical to develop and commercialize nalmefene (a unique dual-acting opioid system modulator, and sold under the brand name Selincro in Europe) in Japan for the reduction of alcohol consumption in adult patients with alcohol dependence.
  • Eli Lilly in its negotiation of a co-development and co-commercialization agreement with Pfizer relating to tanezumab and other hNGF antibodies for the treatment of pain
  • Enzon Pharmaceuticals in the asset sale of its PEGylation Linker Technology platform and related assets to Belrose Pharma
  • Lundbeck in its up to $825 million collaboration with Otsuka Pharmaceutical to develop an experimental Alzheimer's treatment
  • NPS Pharmaceuticals in its termination and transition services agreement with Takeda to re-acquire certain rights to develop and sell Revestive and Preotact
  • Takeda in its collaboration with Resolve Therapeutics to develop compounds for the treatment of lupus (also known as Systemic Lupus Erythematosus, or SLE) and other autoimmune diseases
  • Lundbeck in its agreement with Otsuka Pharmaceutical to promote the drug Abilify in 14 European countries
  • Merck Serono in its option and license agreement valued up to $225 million with Opexa Therapeutics for the development and commercialization of TcelnaTM, a T-cell therapy for those suffering from multiple sclerosis
  • GSK in its up to $335 million research collaboration and license agreement with MD Anderson Cancer Center through its new Institute for Applied Cancer Science (IACS) to develop new therapeutic antibodies that promote an immune system attack against cancer
  • Merck Serono in its development, manufacturing and commercialization collaboration with Dr. Reddy's Laboratories for a portfolio of biosimilar compounds in oncology primarily focused on monoclonal antibodies
  • Enzon Pharmaceuticals in its research, development, and licensing collaboration with Zhejiang Hisun Pharmaceuticals focused on therapeutics using Enzon's PEGylation linker technology, and Hisun's acquisition of development and commercialization rights in China to PEG-SN38, a PEGylated anti-cancer drug
  • Auxilium Pharmaceuticals in its collaboration with Actelion for the development and commercialization of Xiaflex® in Canada, Mexico, Brazil, and Australia
  • Concordia Pharmaceuticals in its asset sale transaction with Kadmon including rights to salirasib, a Phase 2, novel, orally available, small molecule therapeutic in development for the treatment of solid tumors
  • Shire in its co-development and co-commercialization agreement with Shionogi for certain of Shire's ADHD medicines in Japan
  • GSK in its co-development and co-commercialization agreement with Janssen Biologics for sirukumab
  • Lundbeck in its up to $1.8 billion co-development and co-commercialization global alliance with Otsuka Pharmaceutical for up to five innovative psychiatric and neuroscience products worldwide
  • Eli Lilly in its transfer of U.S. rights to sepsis drug Xigris® to BioCritica, a newly created biotech company jointly owned by Lilly, Care Capital, and NovaQuest Capital
  • ViroPharma in its global collaboration and licensing agreement for the subcutaneous combination of Cinryze® (C1 esterase inhibitor [human]) with Halozyme Therapeutics' recombinant human hyaluronidase enzyme (rHuPH20) EnhanzeTM technology
  • Takeda in its up to $750 million development and commercialization collaboration with Intra-Cellular Therapies on selective PDE1 inhibitors for cognitive impairment associated with schizophrenia
  • Lundbeck in its donation together with Novartis of their rights to compound Lu AE58479 for SSADH deficiency to the National Institutes of Health
  • Auxilium Pharmaceuticals in its up to $262 million development, commercialization, and supply collaboration with Asahi Kasei for Xiaflex® in Japan
  • Lundbeck in its drug discovery collaborations with Zenobia Therapeutics and Vernalis plc for inhibitors for LRRK2
  • Invida Group in its exclusive licensing and distribution collaboration with Orexo AB covering the Pacific region for Abstral™
  • Lundbeck in its development and commercialization collaboration agreement with Kyowa Hakko Kirin relating to adenosine A2A antagonist products outside of Japan and the Asia region for all fields, including Parkinson's disease
  • Onyx Pharmaceuticals in its more than $300 million development and commercialization collaboration with Ono Pharmaceutical for Carfilzomib and ONX-0912 in oncology indications in Japan
  • Concordia Pharmaceuticals in its licensing agreement with Ono Pharmaceutical to develop and commercialize salirasib, an agent for the treatment of pancreatic, non-small cell lung and colorectal cancers, in Japan
  • Diamyd Medical AB in its up to $625 million license, development, and commercialization agreement with Ortho-McNeil-Janssen Pharmaceuticals focused on GAD65 antigen-based therapy for the treatment and prevention of type 1 diabetes and associated conditions
  • GlaxoSmithKline in its up to $1.58 billion antisense drug collaboration with Isis Pharmaceuticals for the development and commercialization of therapeutics for rare and infectious diseases
  • Biovail in its acquisition of certain AMPAKINE® compounds and associated intellectual property from Cortex Pharmaceuticals
  • Smiths Detection in its collaboration with Novartis Diagnostics relating to Smiths' Bio-Seeq platform and LATE-PCR technology for use in a range of point-of-care diagnostic tests
  • NPS Pharmaceuticals in the sale of its royalty rights from sales in Asia of REGPARA to a fund managed by DRI Capital for $38.4 million
  • Auxilium Pharmaceuticals in its up to $485 million development, commercialization, and supply collaboration with Pfizer for Xiaflex® in Europe and Eurasia.
  • Profectus BioSciences in the worldwide transfer of Wyeth's therapeutic and prophylactic DNA and vectored vaccine programs for HIV, including NIH contracts providing multimillion dollar funding, as well as HCV, HPV, HSV, and Malaria.
  • Immunomedics in its up to $620 million development and commercialization collaboration with Nycomed for the subcutaneous formulation of its humanized anti-CD20 antibody in non-cancer
  • Takeda in its $100 million up-front and up to $1 billion development and commercialization collaboration and technology transfer transaction with Alnylam relating to RNAi therapeutics
  • Lundbeck in its $100 million up-front and up to $250 million in connection with regulatory approvals, development and commercialization collaboration with Myriad for the Alzheimer's disease drug Flurizan
  • Shire in its up to $325 million development and commercialization collaboration with Alba Therapeutics for gastrointestinal permeability inhibitor AT-1001
  • Adolor in its up to $265 million development and commercialization collaboration with Pfizer for delta opioid agonists
  • Acura Pharmaceuticals in its development and commercialization collaboration with King Pharmaceuticals for opioid analgesic products
  • Shire in its up to $440 million genetic disorders development and commercialization collaboration with Amicus Therapeutics
  • NPS Pharmaceuticals in its licensing collaboration with Nycomed for Gattex
  • Cardiokine in its up to $220 million development and commercialization collaboration with Biogen Idec for lixivaptan, a selective V2 vasopressin receptor agonist
  • Shire in its up to $825 million development and commercialization collaboration with Renovo for Juvista (human TGFß3)
  • Merck in its divestiture of several marketed products to Iroko Pharmaceuticals
  • Lundbeck in its acquisition of Saegis Pharmaceuticals
  • Ambrilia Biopharma in its up to $232 million worldwide licensing agreement with Merck relating to its HIV/AIDS protease inhibitor program
  • Cytogen in the sale of its 50% joint venture interest in the conjugated antibody development and commercialization collaboration, PSMA Development Company LLC, to Progenics
  • Schering-Plough in its global collaboration with Novartis to develop and commercialize a once-daily inhaled fixed-dose combination therapy for asthma and COPD
  • Pharmasset in its development and commercialization collaboration with Bukwang Pharmaceuticals of Korea for the treatment of chronic hepatitis B virus
  • Biovail Pharmaceuticals in its more than $100 million product divestiture, strategic collaboration and research and development alliance with Kos Pharmaceuticals in the area of cardiovascular disease
  • Shire in its up to $500 million collaboration with New River Pharmaceuticals for the development and commercialization of a late-stage ADHD compound
  • Schering-Plough in its acquisition of Bayer AG's primary care pharmaceutical product business in the United States and related strategic alliances on oncology products and on Zetia® in Japan
  • Paul Royalty Fund in its revenue monetization and equity investment in Verus Pharmaceuticals
  • Sanofi-Aventis in the restructuring of its Actonel® collaboration with Procter & Gamble
  • Sanofi-Aventis in its up to $115 million royalty monetization transaction with Paul Royalty Fund relating to sales of Lunesta® by Sepracor
  • Pharmasset in its $300 million collaboration with Roche to develop and commercialize nucleoside polymerase inhibitors for the treatment of chronic hepatitis C virus infections
  • Sanofi-Aventis in its up to $485 million collaboration with Regeneron to develop and commercialize VEGF-Trap products, and related equity investment
  • Quintiles in its co-development and co-promotion collaboration with Eli Lilly for Cymbalta®
  • Cephalon in its $444 million stock-for-stock acquisition of Anesta
  • Sanofi-Aventis in its collaboration with ImmunoGen to discover, develop and commercialize novel antibody-based oncology products
  • Adolor in its worldwide development and commercialization collaboration for Entereg® with GlaxoSmithKline
  • Arena Pharmaceuticals in its drug discovery collaboration with Merck
  • Sanofi-Aventis in its inhaled insulin strategic alliance with Pfizer and related collaboration and licensing arrangements with Nektar Therapeutics

education

  • New York University School of Law, 1982, J.D.
  • Yale University, 1977, B.A.